Molecure SA
WSE:MOC
Intrinsic Value
Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. [ Read More ]
The intrinsic value of one MOC stock under the Base Case scenario is 3.95 PLN. Compared to the current market price of 14.64 PLN, Molecure SA is Overvalued by 73%.
Valuation Backtest
Molecure SA
Run backtest to discover the historical profit from buying and selling MOC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Molecure SA
Current Assets | 87.3m |
Cash & Short-Term Investments | 85m |
Receivables | 829.4k |
Other Current Assets | 1.5m |
Non-Current Assets | 88.2m |
PP&E | 8.6m |
Intangibles | 79.5m |
Current Liabilities | 7.8m |
Accounts Payable | 5.5m |
Accrued Liabilities | 776.7k |
Other Current Liabilities | 1.4m |
Non-Current Liabilities | 3.6m |
Long-Term Debt | 3.3m |
Other Non-Current Liabilities | 324k |
Earnings Waterfall
Molecure SA
Revenue
|
1.4m
PLN
|
Cost of Revenue
|
-1.8m
PLN
|
Gross Profit
|
-424.5k
PLN
|
Operating Expenses
|
-21.1m
PLN
|
Operating Income
|
-21.5m
PLN
|
Other Expenses
|
4.1m
PLN
|
Net Income
|
-17.4m
PLN
|
Free Cash Flow Analysis
Molecure SA
MOC Profitability Score
Profitability Due Diligence
Molecure SA's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Molecure SA's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
MOC Solvency Score
Solvency Due Diligence
Molecure SA's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Molecure SA's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MOC Price Targets Summary
Molecure SA
According to Wall Street analysts, the average 1-year price target for MOC is 26.11 PLN with a low forecast of 25.86 PLN and a high forecast of 26.88 PLN.
Shareholder Return
MOC Price
Molecure SA
Average Annual Return | 75.24% |
Standard Deviation of Annual Returns | 235.32% |
Max Drawdown | -82% |
Market Capitalization | 246.5m PLN |
Shares Outstanding | 16 836 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 106 full-time employees. The company went IPO on 2018-04-19. The firm is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The firm's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The firm has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.
Contact
IPO
Employees
Officers
The intrinsic value of one MOC stock under the Base Case scenario is 3.95 PLN.
Compared to the current market price of 14.64 PLN, Molecure SA is Overvalued by 73%.